NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE144761 Query DataSets for GSE144761
Status Public on Jun 01, 2020
Title Targeting Germline and Tumor Associated Nucleotide Excision Repair Defects in Cancer
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Genetic alterations in members of the nucleotide excision repair (NER) pathway are present in a wide spectrum of cancers, but specific treatment options for this patient population are scarce. Here, we show occurrence of putative damaging germline and somatic alterations in NER genes in up to 10% of patients within certain cancer types across a large set of cancers and explored the potential therapeutic role of irofulven for patients with hypomorphic mutations in nucleotide excision repair genes. Gene-edited isogenic pairs of wildtype and mutant ERCC2 or ERCC3 cell lines were used to assess response to irofulven. Both in vitro and in vivo studies showed significantly enhanced irofulven sensitivity in cells harboring specific clinically observed heterozygous mutations in ERCC2 or ERCC3. Sensitivity of NER mutants to irofulven was greater than to the current standard of care agent cisplatin. Hypomorphic ERCC2/3 mutant cells had an impaired ability to repair irofulven induced DNA damage. Transcriptomic profiling of the tumor tissues suggested co-dependencies between DNA repair pathways, indicating a potential benefit of combination therapies, which were confirmed by in vitro studies. The present study provides a molecularly targeted, pre-clinical approach to cancers with mutations in nucleotide excision repair pathway genes, demonstrating preferential sensitivity to the drug irofulven alone, or in combination with other agents.
 
Overall design Analysis of mRNA expression in xenografts derived from either wildtype human mammary epithelial (HMLE) cells or HMLE cells gene-edited to harbor a heterozygous mutation in ERCC3 (p.R109X). Tumors from eight vehicle treated mice each and tumors from seven mice each treated with irofulven were used for analysis.
 
Contributor(s) Topka S, Steinsnyder Z, Ravichandran V, Tkachuk K, Kemel Y, Bandlamudi C, Madsen MW, Furberg H, Ouerfelli O, Rudin CM, Iyer G, Lipkin SM, Mukherjee S, Solit DB, Berger MF, Bajorin DF, Rosenberg J, Taylor BS, DeStanchina E, Joseph V, Offit K
Citation(s) 33199492
Submission date Feb 04, 2020
Last update date Jul 08, 2021
Contact name Sabine Topka
E-mail(s) topkas@mskcc.org
Phone 6468883188
Organization name MSKCC
Department Medicine
Lab Kenneth Offit
Street address 417 E. 68Th St.Zuckerman Research Bldg.
City New York
State/province NY
ZIP/Postal code 10065
Country USA
 
Platforms (1)
GPL20301 Illumina HiSeq 4000 (Homo sapiens)
Samples (30)
GSM4295260 ERCC3WT/WT vehicle_biological replicate 1
GSM4295261 ERCC3WT/WT vehicle_biological replicate 2
GSM4295262 ERCC3WT/WT vehicle_biological replicate 3
Relations
BioProject PRJNA604811
SRA SRP247196

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE144761_DGEresults_R109XIROvsR109X.csv.gz 1.5 Mb (ftp)(http) CSV
GSE144761_DGEresults_R109XIROvsWTIRO.csv.gz 1.6 Mb (ftp)(http) CSV
GSE144761_DGEresults_R109XvsWT.csv.gz 1.6 Mb (ftp)(http) CSV
GSE144761_DGEresults_WTIROvsWT.csv.gz 1.5 Mb (ftp)(http) CSV
GSE144761_Proj_08988_htseq_all_samples.csv.gz 1.6 Mb (ftp)(http) CSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap